MichaelGoode - Nov 20, 15 1:31 PM[TimAlerts] @BioRunUp $CLDX Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Received 0 Karma